The <scp>ProtekDuo</scp> cannula for extracorporeal membrane oxygenation: A game changer in <scp>COVID</scp>‐19!

Maybauer, Marc O.; Lorusso, Roberto; Swol, Justyna

doi:10.1111/aor.14370

Cited by 8 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This selected group of patients still displayed good outcomes with a survival rate of 67% 12 and the ProtekDuo has been shown to be a game changer when used in patients with ARDS secondary to COVID-19. 13 However, the available data is scarce and may have institutional bias. It should therefore be considered with caution.…”

Section: Discussionmentioning

confidence: 99%

The ProtekDuo in ECMO configuration for ARDS secondary to COVID-19: A systematic review

et al. 2022

Self Cite

View full text Add to dashboard Cite

Objective: Assessment of the results of the ProtekDuo cannula applied for dedicated right ventricular support with oxygenator in ARDS secondary to COVID-19. Methods: Systematic literature search in NHS library, Medline (Pubmed) and EMBASE using appropriate keywords as well as PICOS and PRISMA approach. Results: Out of 285 publications found, 5 publications met the search criteria and were included in this review. A total of 194 patients with ARDS secondary to COVID-19 underwent ProtekDuo placement to establish a combination of respiratory [veno-venous extracorporeal membrane oxygenation (V-V ECMO)] and right ventricular support. Patients treated using the ProtekDuo cannula had survival rates between 59% and 89% throughout the five studies, and a significant survival benefit when compared to an invasive ventilation group or compared to dual site V-V ECMO or other double lumen ECMO cannulas. One study focused on extubation and discontinuation of ventilator support, which could be achieved in 100% of ProtekDuo patients. An association for reduced incidence of acute kidney injury (AKI) and use of continuous renal replacement therapy (CRRT) could be shown when the ProtekDuo was used. Conclusion: Only limited literature is available for the ProtekDuo in V-P ECMO configuration in the setting of COVID-19 ARDS and should be interpreted with caution. Data on the ProtekDuo is suggestive for lower rates of mortality, AKI and CRRT as compared to other respiratory support modalities.

show abstract

Section: Discussionmentioning

confidence: 99%

The ProtekDuo in ECMO configuration for ARDS secondary to COVID-19: A systematic review

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the overall review of these studies, the ProtekDuo for VP ECMO has become a game changer for patients with COVID-19 ARDS. However, available studies and data are scarce and are at risk for institutional bias and should be considered with caution [28]. Lastly, studies of non-COVID-19 ARDS patients treated with ECMO configurations utilizing the ProtekDuo® cannula are needed.…”

Section: Clinical Evidence For the Protekduo® In Respiratory Ecmo Sup...mentioning

confidence: 99%

Adaptive ECMO Therapeutics: The Integral Role of the ProtekDuo® Cannula

Brewer,

Dacey,

O. Maybauer

2024

Evolving Therapies and Technologies in Extracorporeal Membrane Oxygenation [Working Title]

View full text Add to dashboard Cite

This chapter provides an in-depth analysis of the ProtekDuo® (LivaNova, London) dual-lumen cannula’s application in extracorporeal membrane oxygenation (ECMO), focusing on the procedural techniques of cannulation, weaning, and decannulation. The discussion will provide the step-by-step methodologies for inserting and removing the cannula, drawing from current clinical practices. Further, the chapter will explore the range of ECMO configurations that the ProtekDuo® cannula enables. It will examine how these configurations can be tailored to the evolving clinical requirements of patients, thereby enhancing the adaptability and effectiveness of ECMO therapy. This analysis will be anchored in the latest literature, providing a contemporary overview of patient outcomes and current practices. Lastly, the chapter will project into the future of the cannula technology for venopulmonary (VP) ECMO and other configurations. It will review ongoing research and development efforts, speculate on potential technological breakthroughs, and discuss the implication of these innovations for clinical practice. This forward-looking perspective will aim to inform and inspire continued advancement in ECMO therapy and technology.

show abstract

“…After the pump, the tubing was spliced with a 3/8” Y-connector and arterialized blood was returned to the patient through both lumina of the ProtekDuo, thereby giving arterialized blood to the RA and pulmonary artery (Figure 4(b)). 20…”

Section: Configurations Technical Aspects and Present Evidencementioning

confidence: 99%

“…After the pump, the tubing was spliced with a 3/8" Y-connector and arterialized blood was returned to the patient through both lumina of the ProtekDuo, thereby giving arterialized blood to the RA and pulmonary artery (Figure 4(b)). 20 During ECMO support, the ProtekDuo is used in its position as RVAD with the addition of an oxygenator. However, in this V-P configuration, blood flow may be limited, and considerable shunting may occur in patients with tachycardia, anxiety or other situations that increase the native cardiac output.…”

Section: Protekduo In V-vp Ecmo Configuration As Double Lumen Return ...mentioning

confidence: 99%

The novel ProtekDuo ventricular assist device: Configurations, technical aspects, and present evidence

et al. 2022

View full text Add to dashboard Cite

The ProtekDuo, single site dual lumen cannula can be used in a multitude of configurations. In the medical literature, the ProtekDuo is described as right ventricular assist device (RVAD), as left ventricular assist device (LVAD), as biventricular assist device (BiVAD) when combined with an Impella device or other LVAD’s, as double lumen drainage cannula on cardiopulmonary bypass (CPB), as RVAD with oxygenator, in veno-pulmonary (V-P) ECMO configuration, venovenous-pulmonary (VV-P) ECMO configuration with additional drainage cannula, and in veno-venopulmonary (V-VP) ECMO configuration as double lumen return cannula. Improvements in flow and oxygenation have been recognized in various settings and need further scientific evaluation. We summarized the above-mentioned configurations, technical aspects, and the present literature available for the ProtekDuo.

show abstract

The ProtekDuo cannula for extracorporeal membrane oxygenation: A game changer in COVID‐19!

Cited by 8 publications

References 7 publications

The ProtekDuo in ECMO configuration for ARDS secondary to COVID-19: A systematic review

The ProtekDuo in ECMO configuration for ARDS secondary to COVID-19: A systematic review

Adaptive ECMO Therapeutics: The Integral Role of the ProtekDuo® Cannula

The novel ProtekDuo ventricular assist device: Configurations, technical aspects, and present evidence

Contact Info

Product

Resources

About